SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high capital expenditures in AI infrastructure and potential execution risks, fueling a volatile debate in the community about whether this represents a long-term value opportunity or a structural decline. While some traders are expressing extreme frustration over the stock's persistent underperformance relative to broader market indices, others are highlighting the company's strong cash flows and cloud leadership as reasons to view current price levels as an attractive entry point for the long term.

The Shrimp Army

The Shrimp Army is gaining traction as part of a broader trend of sea-themed memecoins, sparking intense debate among community members over its potential for rapid growth versus risks of being a speculative pump-and-dump. Traders are actively monitoring the token's ability to maintain upward momentum and consolidate at higher valuation levels.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant downward pressure as investors react to a Google Research blog post regarding TurboQuant, an algorithmic compression method that some fear could reduce long-term demand for high-bandwidth memory. While the broader community is deeply divided between those viewing the sell-off as an algorithmic panic driven by misunderstanding and those concerned about cyclical memory sector headwinds, many retail traders are actively debating whether to accumulate shares on the dip or exit to avoid further downside.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense selling pressure as investors react to potential regulatory hurdles regarding prediction markets and ongoing legal challenges surrounding the NCAA. The community is heavily polarized, with many retail traders actively loading puts and voicing frustration over consistent insider selling while others view the pullback as a potential buying opportunity.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is currently in the spotlight following a short-seller report from Culper Research that alleges channel stuffing and financial irregularities, which the company has formally dismissed as containing misleading and inaccurate statements. The community is actively debating the credibility of these allegations, with many long-term shareholders expressing strong conviction in management's integrity and focusing on upcoming earnings as a potential catalyst for a rebound.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members point to signs of quiet accumulation and a potential bullish reversal for the gaming token. Traders are actively debating the token's role in the future of on-chain gaming economies, with sentiment divided between optimism for a recovery and frustration over recent volatility.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors debate whether the fund's parabolic run is driven by genuine exposure to high-growth AI and aerospace giants like SpaceX and Anthropic or if it has entered bubble territory due to its massive premium to Net Asset Value. The community remains sharply divided, with many actively hunting for alternative "catch-up" plays like DXYZ and RVI while others warn of a potential liquidity trap once lock-up periods expire.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is seeing heightened trading volume and community interest driven by persistent speculation regarding an upcoming SpaceX IPO, which remains a primary holding for the fund. Investors are actively debating the valuation premium relative to its net asset value compared to other proxies, while sentiment remains bullish on the fund's concentrated exposure to high-growth unicorns like Anthropic and OpenAI.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors react to the launch of Costco's private-label energy drink, which has sparked heated debate over potential market share erosion and the strength of the brand's moat. While some in the community see the sell-off as an emotional overreaction and a buying opportunity, others are expressing concern over cooling growth data and perceived management failures, leading to significant volatility.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan shares are seeing significant volatility as investors digest a string of strong earnings results and upbeat fiscal outlooks, while the broader community debates whether the AI-integrated platform is a long-term disruptor or facing undue selling pressure. Much of the active discussion centers on the company's recent margin expansion and revenue growth versus persistent concerns regarding its IPO performance and general market sentiment toward SaaS-based travel tech.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12.</li><li>The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.</li><li>Wedbush stated that it has “limited conviction and visibility” regarding StubHub’s direct issuance business.</li></ul>StubHub Holdings Inc.’s (STUB) lackluster fourth-quarter (Q4) results drew a spate of downgrades from Wall Street, with analysts pointing to a series of concerns about the company’s future outlook and the regulatory environment.<a href="https://stocktwits.com/symbol/STUB">StubHub shares</a> tumbled more than 14% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Worried?</h2>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12. The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.JPMorgan stated that StubHub’s 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance is now 60% lower than what the company projected in October 2025. The firm said that while the new outlook “may finally be achievable,” it will have to work through the lock-up expiration beginning March 9, 2026, and also overcome ongoing regulatory concerns around the company.Analysts at Wedbush also downgraded StubHub to ‘neutral’ from ‘outperform’ and lowered the price target by 80% to $10 from $18. The firm stated that it has “limited conviction and visibility” in StubHub’s direct issuance business, noting that the ticket resale broker’s management’s “lofty” expectations are not materializing.Wedbush also stated that regulatory risks will remain an overhang on the stock, while adding that the company is vulnerable to AI-enabled disintermediation in the coming years, given that companies operating in the space face the risk from commoditization.<h2 class="st-heading-2">StubHub’s Q4 At A Glance</h2>StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share (EPS) of $0.13 during the same quarter a year ago. Wall Street expected the company to report a loss of $0.02 per share during the quarter, according to Fiscal.ai data.The company’s revenue in Q4 was $449 million, down from $533 million in the year-ago period. Wall Street consensus projected StubHub to report revenue of $485 million during the period.StubHub’s founder and CEO, Eric Baker, remained optimistic about the company’s prospects, stating that 2025 reinforced that the ticket resale broker’s mission is as relevant as ever. “Our full-year performance validates our long-term strategy and the substantial value we're creating for fans, partners, and shareholders alike,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React To STUB?</h2>One user on Stocktwits pointed to macroeconomic challenges in the U.S., adding that the amount of money people have to spend on “luxuries” is declining.<stembedurl>https://stocktwits.com/insanitywolftrading/message/646656600</stembedurl>However, a bullish user said that StubHub is a “solid company with actually great earnings.”<stembedurl>https://stocktwits.com/llevi/message/646632021</stembedurl><a href="https://stocktwits.com/symbol/STUB">STUB stock</a> is down 25% year-to-date and 64% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-stock-soars-q4-beat-palladyne-ai-ceo-touts-deeper-defense-engagement/cZdQqg1RI3P">Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The StubHub logo and webpage are displayed on a cell phone and computer monitor. (Photo Illustration by Mario Tama/Getty Images)

StubHub's Q4 Miss Draws Multiple Downgrades From Wall Street – Analysts Warn Of ‘Credibility’ Gap

StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share of $0.13 during the same quarter a year ago, while Wall Street expected a loss of $0.02 per share.

Equity

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.</li><li>It said that the Wakix franchise delivered net revenue of approximately $239 million in the third quarter.&nbsp;</li></ul>Shares of Harmony Biosciences Holdings (HRMY) jumped 6% in the premarket session on Thursday after the company raised its full-year revenue guidance on strong Wakix sales.The firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251023496242/en/Harmony-Biosciences-Preannounces-Strong-Q3-2025-WAKIX-Performance-Raises-2025-Revenue-Guidance">expects</a> full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.<h2 class="st-heading-2">Excessive Sleepiness Medication Drives Revenue</h2>The company said that its Wakix franchise delivered net revenue of approximately $239 million in the third quarter (Q3), representing 29% year-over-year revenue growth. Wakix is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, causing excessive daytime sleepiness and uncontrollable sleep attacks. Other symptoms include sudden loss of muscle control called cataplexy. The company said the increase in Wakix revenue was driven by higher average patient volume.The company is expected to report full Q3 earnings on November 4.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained at ‘low’ levels.Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">announced</a> that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance due to a higher-than-expected placebo response rate. Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability.CEO Jeffrey M. Dayno then highlighted the company’s strong portfolio, noting that it is on track to initiate late-stage trials of Wakix in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year.HRMY shares are down 24% this year and by about 23% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-nearly-64000-cybertrucks-over-concerns-with-front-parking-lights/cLG4hXGR3AH">Tesla Recalls Nearly 64,000 Cybertrucks Over Concerns With The Front Parking Lights</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?

The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.

Is Now the Time to Buy Small-Cap Stocks?

We discuss the outlook for small-cap stocks and highlight four ETFs.

The Zacks Analyst Blog Highlights MCOW, SCOW, SFLO and CALF

Pacer???s new MCOW and SCOW ETFs spotlight quality small- and mid-cap firms with strong free cash flow, joining rivals SFLO and CALF.

Looking for Quality ETFs in Smaller Caps? Tap 2 New FCF Aristocrats 

MCOW and SCOW debut with quality-focused strategies, targeting mid- and small-cap stocks with strong free cash flow records.



SFLO
Victory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SFLO News

SFLOVictory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF